It is always better to wait for a replacement than to inject a compromised substance
SURPASS-1 shows that tirzepatide alone, at all doses, was superior to placebo and revealed a dose-dependent reduction of HbA1c by up to 2.07% (p 10% weight loss can be disease modifying and may even lead to disease remission [38]
[DOI] [PMC free article] [PubMed] [Google Scholar] 190.Yu L., Quinn M.T., Cross A.R., Dinauer M.C
On note, GLP-1 receptor agonists arent advised for individuals who: Have had Neuroendocrine tumours (NETs) or medullary thyroid cancer or have a genetic predisposition to the disease
As GLP-1R-targeted nanomedicines advance toward clinical application, an in-depth understanding of nanomaterialimmune system interactions, long-term retention effects, and rigorous toxicological validation will be essential for ensuring safety, regulatory approval, and patient benefit in metabolic, cardiovascular, and neurodegenerative disease settings
